miR-378d suppresses malignant phenotype of ESCC cells through AKT signaling

BACKGROUND: Post-resistance progress in paclitaxel (PTX) treatment remains a major challenge in tumor treatment. A high dose of PTX was used for cell lines to analyze the changes in molecular expression. The miR-378d was sharply reduced in surviving cells, but the role of miR-378d in Esophageal squa...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jie, Shi, Susu, Yu, Juan, Liu, Jianli, Wei, Haixiang, Song, Haixia, Wang, Shaoqiang, Li, Zhejie, He, Shujin, Li, Lei, Zhang, Hongyan, Yan, Zhizhen, Zhao, Ran, Liu, Yukun, Liu, Yanrong, Li, Junjun, Zhang, Renya, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8697470/
https://www.ncbi.nlm.nih.gov/pubmed/34937563
http://dx.doi.org/10.1186/s12935-021-02403-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8697470/
https://www.ncbi.nlm.nih.gov/pubmed/34937563
http://dx.doi.org/10.1186/s12935-021-02403-y

Ejemplares similares